Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia

Lauren Scherer, Candise Tat, Tim Sauer, Haruko Tashiro, Swati Naik, Mireya Paulina Velasquez, Stephen Gottschalk, Cliona M. Rooney, Malcolm K. Brenner, Bilal Omer

Blood (2022) 140 (Supplement 1): 7396–7397.

https://doi.org/10.1182/blood-2022-170503

Published: 2022

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Blood (2022) 139 (17): 2706–2711.

https://doi.org/10.1182/blood.2021014648

Published: 2022

Includes: Supplemental data

Journal Articles

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Blood (2021) 138 (Supplement 1): 471.

https://doi.org/10.1182/blood-2021-149332

Published: 2021

Journal Articles

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer, Kathan Parikh, Sandhya Sharma, Bilal Omer, David Sedloev, Qian Chen, Linus Angenendt, Christoph Schliemann, Michael Schmitt, Carsten Müller-Tidow, Stephen Gottschalk, Cliona M. Rooney

Blood (2021) 138 (4): 318–330.

https://doi.org/10.1182/blood.2020008221

Published: 2021

Includes: Supplemental data

Journal Articles

Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

Ifigeneia Tzannou, MD, Ayumi Watanabe, Bsc, Anastasia Papadopoulou, PhD, Manik Kuvalekar, Msc, Swati Naik, MBBS, Premal Lulla, MBBS, Robert A. Krance, MD, Carlos A. Ramos, MD, Helen E. Heslop, MD DSc, Ann M. Leen, PhD, Bilal Omer, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-143037

Published: 2020

Journal Articles

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity

Tim Sauer, MD, Kathan Parikh, Sandhya Sharma, Bilal Omer, MD, Stephen Gottschalk, MD, Cliona M. Rooney, PhD

Blood (2019) 134 (Supplement_1): 1932.

https://doi.org/10.1182/blood-2019-125534

Published: 2019

Journal Articles

Myeloablative Conditioning with Alemtuzumab in Matched Related Donor Hematopoietic Cell Transplant for Sickle Cell Disease Prevents Graft-Versus-Host Disease without Compromising Engraftment

Tami D John, MD, Khaled Yassine, MD, Swati Naik, MBBS, Ghadir Sasa, MD, Bilal Omer, MD, Caridad A. Martinez, MD, Priti Tewari, MD, Robert A. Krance, MD, Kathryn S Leung, MD

Blood (2018) 132 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2018-99-113856

Published: 2018

Journal Articles

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Blood (2017) 130 (Supplement 1): 4484.

https://doi.org/10.1182/blood.V130.Suppl_1.4484.4484

Published: 2017

Journal Articles

Safety and Preliminary Efficacy of "Ready to Administer" Cytomegalovirus (CMV)-Specific T Cells for the Treatment of Patients with Refractory CMV Infection

Ifigeneia Tzannou, MD, Kathryn S. Leung, Caridad Martinez, MD, Swati Naik, MD, Stephen Gottschalk, MD, Adrian P. Gee, PhD, Bambi Grilley, Ayumi Watanabe, Ann M. Leen, PhD, Sunitha Kakarla, PhD, Bilal Omer, MD

Blood (2016) 128 (22): 388.

https://doi.org/10.1182/blood.V128.22.388.388

Published: 2016

Journal Articles

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Ifigeneia Tzannou, MD, Anastasia Papadopoulou, PhD, Ayumi Watanabe, Manik Kuvalekar, Adrian P. Gee, PhD, Swati Naik, MD, Caridad Martinez, MD, Kathryn S. Leung, Ghadir S. Sasa, MD, Robert A. Krance, MD, George Carrum, MD, Carlos A. Ramos, MD, Bambi Grilley, Malcolm K. Brenner, MD PhD, Cliona M. Rooney, PhD, Helen E Heslop, MD DSc (Hon), Ann M. Leen, PhD, Bilal Omer, MD

Blood (2016) 128 (22): 501.

https://doi.org/10.1182/blood.V128.22.501.501

Published: 2016

Journal Articles

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Bilal Omer, MD, Anastasia Papadopoulou, PhD, Nikita Koottiyaniyil, Adrian P. Gee, PhD, Swati Naik, MD, Caridad Marinez, MD, Leung Kathryn, MD, Ghadir S. Sasa, MD, Robert A. Krance, MD, Bambi Grilley, RPh, Malcolm K. Brenner, MD PhD, Cliona M. Rooney, PhD, Helen E. Heslop, MD, Ann M. Leen, PhD, Ifigeneia Tzannou, MD

Blood (2015) 126 (23): 622.

https://doi.org/10.1182/blood.V126.23.622.622

Published: 2015

Journal Articles

Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years

Ifigeneia Tzannou, MD, Bilal Omer, MD, Anastasia Papadopoulou, PhD, Ulrike Gerdemann, MD, Colton Smith, PhD, Adrian P. Gee, PhD, Bambi J Grilley, Malcolm K. Brenner, MB, PhD FRCP, FRCPath, Catherine M. Bollard, MD, Ann M. Leen, PhD, Cliona M. Rooney, PhD, Helen E. Heslop, MD

Blood (2015) 126 (23): 1926.

https://doi.org/10.1182/blood.V126.23.1926.1926

Published: 2015

NARROW

LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity

Myeloablative Conditioning with Alemtuzumab in Matched Related Donor Hematopoietic Cell Transplant for Sickle Cell Disease Prevents Graft-Versus-Host Disease without Compromising Engraftment

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Safety and Preliminary Efficacy of "Ready to Administer" Cytomegalovirus (CMV)-Specific T Cells for the Treatment of Patients with Refractory CMV Infection

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only